Bone resorption predicts for skeletal complications in metastatic bone disease - Wikidata - awgldk - TriplyDB

Bone resorption predicts for skeletal complications in metastatic bone disease

Bone resorption predicts for skeletal complications in metastatic bone disease

http://www.wikidata.org/entity/Q36648116

about

Denosumab Natural history of malignant bone disease in breast cancer and the use of cumulative mean functions to measure skeletal morbidity.Recent developments in bisphosphonates for patients with metastatic breast cancer.Molecular pathogenesis of bone metastases in breast cancer: Proven and emerging therapeutic targets Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13.Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review Breast cancer metastasis to the bone: mechanisms of bone loss The science and practice of bone health in oncology: managing bone loss and metastasis in patients with solid tumors Renal cell carcinoma bone metastases: clinical advances Breast Cancer: Rank Ligand Inhibition.Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion How do we estimate survival? External validation of a tool for survival estimation in patients with metastatic bone disease-decision analysis and comparison of three international patient populations.Use of urinary markers in cancer setting: A literature review Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial.Bisphosphonates in breast cancer.Bisphosphonates and bone metastases: current status and future directions.Clinical use of markers of bone turnover in metastatic bone disease.A primer of bone metastases management in breast cancer patients.The role of the bone microenvironment in skeletal metastasis.Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients With Bone Metastases Undergoing Treatment With Bone-Modifying Agents.New and emerging therapies for bone metastases in genitourinary cancers.The use of molecular markers of bone turnover in the management of patients with metastatic bone disease.Pharmacotherapy of bone metastases in breast cancer patients.Optimal management of bone metastases in breast cancer patients.Treatment options for breast cancer and bone metastases.Role of denosumab in breast cancer.Emerging therapeutic targets in breast cancer bone metastasis.The use of bisphosphonates in cancer treatment.Progress in the treatment of bone metastases in cancer patients.Biomarkers of bone turnover in diagnosis and therapy of osteoporosis: a consensus advice from an Austrian working group.Biomarkers of bone turnover in oncology: applications in diagnosis and treatment.Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid.Elevated N-telopeptide as a potential diagnostic marker for bone metastasis in lung cancer: A meta-analysis.Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.Serum cross-linked n-telopeptides of type 1 collagen (NTx) in patients with solid tumors.Biochemical markers of bone metabolism in breast cancer.

P2860

Q24651938-213EAA22-48CE-45BA-AA70-CD3558AAE065 Q33491284-579DE5E3-B8EA-43F8-B461-75219E2819BE Q33935632-EFE66DB0-829E-4530-BE5F-A16F4E9556E1 Q34023663-4C9F3A46-D934-4A5A-B164-2D19A87744C9 Q34041808-C0010CF6-F1AF-483E-BACA-26E562FB351C Q34325491-81B89D43-CBFE-4D89-B348-8C8B4EC1C29A Q34571005-20011AE9-4066-4A01-BDB3-C4305B07A1A7 Q34613578-3C2C2398-8C3D-45D0-8FCE-B0FF2FB2D107 Q34617864-2BA246F7-C6C1-4EF1-B645-5CC830223950 Q34631216-49E29619-E8A5-4CDD-A638-568E17494C95 Q35095558-9AF27704-22F0-4A44-80D8-E827DDD85FAF Q35205280-30844338-33A1-435D-B617-0977480BED91 Q35638675-1FB14E8C-7A8D-44E1-B64F-8ADAF6B9BA04 Q35844765-93509585-2023-43D9-B4A3-2876900C5736 Q35959956-4AC7825C-1834-4067-B9E1-FF67DAC9153C Q36085307-E595442E-6A47-4387-AC0E-AD7893E6F118 Q36118409-58AEEFE7-173F-49C9-9058-458FEAC34638 Q36277211-7678D40E-8830-4606-A81B-F5AF1C501EED Q36410656-F7C4B653-D512-4C78-ACD3-9ACF7A9F9746 Q36491430-C45F2A2D-D24E-4C96-96FA-5EFDFE91B744 Q36696468-93C1B09C-87FB-4541-BE8B-A12F3DD4F4FF Q36788277-DB2C6DD8-611D-43D6-89EE-B1C776FC3D5E Q36866291-8BC4B252-7B76-4A4C-BD9A-D2DD0824BCB1 Q36990793-45755763-F31A-40A6-BB2B-C7DB547E01CF Q37123398-B7F66B13-04F3-4B1A-984F-9514B40EA287 Q37355487-A7870C56-A85A-4A37-B569-AB46C2ECF3BC Q37401841-8546CEE5-908F-4B08-B674-9181E1831615 Q37571986-AF2FA6EB-B997-415F-B636-C1BE6ED39370 Q37658767-7A3FAEA0-C03F-4307-A59B-4704B513AE70 Q37800183-84C95B0E-C448-4BF7-B820-D9CC12A116D6 Q38002450-1143B81D-D34E-4CE5-8C6F-C50E28EBEB55 Q38034435-173861F6-50D1-4819-B29B-F6C5F2162FDE Q38088714-D26D7578-C23B-49C7-8CFD-674F494AAC39 Q38364467-984B77DA-3F60-49F8-9CA8-F2BC95ADC4A8 Q40236861-A4BF42FA-774C-4FF0-AEB0-C6518E18E369 Q41594636-8080218F-F2FB-45F2-8B23-58562EE969F4 Q47099452-9E3B63EF-47C7-459B-A332-93DF45224EC1 Q47146433-F81370E4-E8BF-4B73-BD5E-DC6B3C468B73 Q47733526-9F62EC81-09A2-41E2-A092-BC15D9C77F01 Q54437560-14EEBC58-5AFD-499C-88A7-38DD373D1E23

P2860

Bone resorption predicts for skeletal complications in metastatic bone disease

http://www.wikidata.org/entity/Q36648116

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Bone resorption predicts for skeletal complications in metastatic bone disease

@ast

Bone resorption predicts for skeletal complications in metastatic bone disease

@en

type

label

Bone resorption predicts for skeletal complications in metastatic bone disease

@ast

Bone resorption predicts for skeletal complications in metastatic bone disease

@en

prefLabel

Bone resorption predicts for skeletal complications in metastatic bone disease

@ast

Bone resorption predicts for skeletal complications in metastatic bone disease

@en

P1433

Q36648116-B2B9281F-808E-4590-8E67-84A3649C2E06

P1476

Q36648116-775355F0-15FC-4853-AA61-89D1E5813AB6

P2093

Q36648116-199EFBC9-8CBA-4A6C-9B76-9428458DE11C

Q36648116-92591AD7-04CB-45EC-B561-9B319DE906AE

Q36648116-A3D0788B-676A-45C8-BCE7-A82716614D92

Q36648116-B2FDCEC2-2AFD-4980-8155-71AF076B209B

Q36648116-D9F19AAE-267B-4BA0-8E7D-F68FE4B0A988

Q36648116-E3A757B1-CC75-422C-B191-D22DC27F303F

P2860

Q36648116-04E7914B-2401-4F4A-BA03-E53F9006A111

Q36648116-15CC0799-12D6-4027-A5E4-D3851FD9EA48

Q36648116-2A051104-4641-4095-AA51-6FCE2469435A

Q36648116-4DE2FD40-1CA6-46BA-83C9-2001A841ABE6

Q36648116-65E2BF18-9A6D-44B4-9CAD-07340C9F5DB8

Q36648116-75D4BD31-B791-4D3C-B2A1-796A5652FE16

Q36648116-917EC60B-3B7C-403C-8C95-EC58E3B60D3E

Q36648116-B6DE93BF-0797-460E-AEB3-DA43509653C0

Q36648116-BD9BB46A-084F-42D3-AC9B-5DC93B82244E

Q36648116-CC1DBDB2-6E13-4078-A734-905FC17C3058

P2888

Q36648116-F93FF8B4-4773-465B-A844-AE4658E7EDEC

P304

Q36648116-B922265F-9289-4875-BCD2-8CE2D38AC244

P31

Q36648116-D0222102-B03E-4693-B6F9-B4FA0C30E492

P356

Q36648116-7CAB25DB-F73B-4745-9795-2BE229E60073

P407

Q36648116-80830DBD-8027-493A-B476-F841407CE2B9

P433

Q36648116-6FF9F399-4F6A-42C1-A187-6690CFFDB772

P478

Q36648116-D5847817-C255-41B8-9809-FA3D3369FA0F

P577

Q36648116-40C3D58C-BE52-443A-B5A2-6769FC1BB106

P5875

Q36648116-9D15B98A-776C-431C-A5B6-4C66CADAF53A

P698

Q36648116-8BEDA9F0-B936-4269-ABFD-944404265FC4

P932

Q36648116-97EFDBCA-CD74-4A2F-90AF-D194AAFF4306

P356

P1433

British Journal of Cancer

P1476

Bone resorption predicts for skeletal complications in metastatic bone disease

@en

P2093

C S Thomson

http://www.w3.org/2001/XMLSchema#string

J E Brown

http://www.w3.org/2001/XMLSchema#string

O P Purohit

http://www.w3.org/2001/XMLSchema#string

R E Coleman

http://www.w3.org/2001/XMLSchema#string

S A Gutcher

http://www.w3.org/2001/XMLSchema#string

S P Ellis

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Bone markers in the management of metastatic bone disease.

Analysis of skeletal-related events in breast cancer and response to therapy.

Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease.

Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors.

Advanced breast cancer: use of resources and cost implications

The clinical course of bone metastases from breast cancer.

Metabolic effects of pamidronate in patients with metastatic bone disease.

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.

Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.

P2888

P304

2031-2037

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6601437

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

89

http://www.w3.org/2001/XMLSchema#string

P577

2003-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8984000

http://www.w3.org/2001/XMLSchema#string

P698

14647134

http://www.w3.org/2001/XMLSchema#string

P932

2376859

http://www.w3.org/2001/XMLSchema#string